MK-2894

• Description:

  MK-2894 is a potent, selective, orally active and high affinity (Ki=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC50=2.5 nM) . MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis[1][2].

• UNSPSC:

  12352005

• Target:

  Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/MK-2894.html

• Concentration:

  10mM

• Purity:

  99.31

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O=C(O)C1=CC=C(C2(NC(C3=C(C)SC(C)=C3CC4=CC=C(C(F)(F)F)C=C4)=O)CC2)C=C1

• Molecular Formula:

  C25H22F3NO3S

• Molecular Weight:

  473.51

• References & Citations:

  [1]Blouin M, et al. The discovery of 4-{1-[ ({2,5-dimethyl-4-[4- (trifluoromethyl) benzyl]-3-thienyl}carbonyl) amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. J Med Chem. 2010 Mar 11;53 (5) :2227-38.|[2]Tijana Markovič, et al. Structural features of subtype-selective EP receptor modulators. Drug Discov Today. 2017 Jan;22 (1) :57-71.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  EP

• CAS Number:

  1006036-87-8